Dar? Bioscience, Inc. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
DARE Nasdaq 3850 darebioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dar? Bioscience, Inc.

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025 - May 6th, 2025 12:00 pm
Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation - Apr 23rd, 2025 12:00 pm
Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year - Apr 7th, 2025 12:00 pm
Q4 2024 Dare Bioscience Inc Earnings Call - Apr 1st, 2025 1:56 pm
Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... - Apr 1st, 2025 7:03 am
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates - Mar 31st, 2025 9:15 pm
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update - Mar 31st, 2025 8:01 pm
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 - Mar 24th, 2025 12:00 pm
Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant - Feb 20th, 2025 1:00 pm
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development - Feb 6th, 2025 1:00 pm
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 9th, 2025 1:00 pm
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) - Dec 16th, 2024 1:00 pm
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% - Dec 10th, 2024 1:00 pm
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 - Dec 4th, 2024 1:00 pm
Q3 2024 Dare Bioscience Inc Earnings Call - Nov 15th, 2024 6:54 pm
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Nov 15th, 2024 7:19 am
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - Nov 14th, 2024 10:10 pm
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update - Nov 14th, 2024 9:01 pm
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites - Nov 13th, 2024 1:00 pm
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know - Nov 7th, 2024 5:00 pm